Compare Abeona Therapeutics Inc (ABEO) vs Union Pacific Corporation (UNP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Union Pacific Corporation — how do they compare? Abeona Therapeutics Inc trades at $6.77 (market cap $373.32M), while Union Pacific Corporation trades at $280.51 (market cap $168.09B). The key difference: Union Pacific Corporation is far larger — about 450.3× Abeona Therapeutics Inc's market cap, and Union Pacific Corporation pays a 1.95% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | UNP | |
|---|---|---|
Market Cap | $373.32M | $168.09B |
Sector | Health | Industrials |
52-Week High | $7.23 | $283.12 |
52-Week Low | $4.17 | $214.91 |
Enterprise Value | $228.22M | $198.56B |
Dividend Yield | — | 1.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Union Pacific (UNP) trades at $283.12, up 0.31% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported strong Q1 2026 earnings, beating estimates with EPS of $2.93, and maintains robust profitability with a 29.2% net margin. Recent news highlights the ongoing merger process with Norfolk Southern and a class action lawsuit regarding environmental concerns.
Outlook remains positive with a consensus price target of $290.55, indicating potential upside. Key risks include regulatory scrutiny of the merger and legal challenges. The stock's valuation multiples are elevated, but solid cash flow and dividend growth support investor confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Union Pacific Corporation
Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two thirds of the U.S., UP generated roughly $22 billion of revenue in 2021 by hauling coal, industrial products, intermodal containers, agriculture goods, chemicals, and automotive goods. UP owns about one fourth of Mexican railroad Ferromex and derives about 10% of its revenue hauling freight to and from Mexico.
Read more on UNP →
